Atea and Roche get a Covid-19 antiviral warning
The failure of the phase 2 Moonsong outpatient trial prompts a phase 3 rethink and a one-year delay.
Takeda gets the pipeline blues
A big selloff on a mid-stage stumble seems harsh, but Takeda has problems on the horizon.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
Oncology the focus for big pharma catalysts
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Edesa finds a signal in severely ill Covid-19 patients
But other small biotechs are more advanced and still hope to play a role in the pandemic.
